Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03228914 · ClinicalTrials.gov registry record · Phase 4
Comparing Blood Loss and Visualization After the Preoperative Use of Topical 0.05% Oxymetazoline Versus 1:1000 Epinephrine Prior to Endoscopic Sinus Surgery
A Phase 4 study of Nasal Polyps and Endoscopic Sinus Surgery, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03228914: Completed Phase 4 study of Nasal Polyps and Endoscopic Sinus Surgery, sponsored by The University of Texas Health Science Center, Houston.
NCT03228914 is a Phase 4 study of Nasal Polyps and Endoscopic Sinus Surgery that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 20 participants, below the 100-participant average among 7 other Nasal Polyps trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03228914, a Phase 4 study of Nasal Polyps and Endoscopic Sinus Surgery, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the effects of Oxymetazoline and Epinephrine (which are 2 different nasal decongestants both of which are routinely used before sinus surgery) on blood loss and the surgeon's view of the surgical field during sinus surgery.
Primary Outcome
The minimum Boezaart Grading Scale score of 0 indicates no bleeding (cadaveric conditions), and the maximum score of 5 indicates severe bleeding (constant suctioning required).
Conditions Studied
Interventions
- DRUG Epinephrine
- DRUG Oxymetazoline
Study Locations (1)
Texas
- The University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-06-14 |
| Est. Completion | 2018-08-29 |
| Phase | Phase 4 |
What the finished NCT03228914 record still lists
NCT03228914 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 100-participant average among 7 other Nasal Polyps trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with Nasal Polyps appearing as the primary indexed condition, and to 2 interventions - of which Epinephrine is the first listed.
NCT03228914 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03228914 about?
NCT03228914 is a clinical study titled "Comparing Blood Loss and Visualization After the Preoperative Use of Topical 0.05% Oxymetazoline Versus 1:1000 Epinephrine Prior to Endoscopic Sinus Surgery". The purpose of this study is to compare the effects of Oxymetazoline and Epinephrine (which are 2 different nasal decongestants both of which are routinely used before sinus surgery) on blood loss and the surgeon's view of the surgical field during sinus surgery.
What is the current status of trial NCT03228914?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2018-06-14. Estimated completion is 2018-08-29.
What conditions does trial NCT03228914 study?
This clinical trial studies the following conditions: Nasal Polyps, Endoscopic Sinus Surgery.
What interventions are being tested in trial NCT03228914?
The interventions under investigation include: Epinephrine (DRUG), Oxymetazoline (DRUG).
Who is sponsoring clinical trial NCT03228914?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03228914 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nasal Polyps
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP
RECRUITING · Phase 4
-
Dupixent Study for Alternate Administration
ACTIVE NOT RECRUITING · Phase 4
-
Does Batten Grafting Improve Nasal Outcomes in Septoplasty and Turbinate Reduction?
RECRUITING · NA
-
Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease
ACTIVE NOT RECRUITING · Phase 2
-
The Polymerase Chain Reaction (PCR) Analysis of Nasal Polyps for Fungal DNA
COMPLETED · NA
-
Qualitative Analysis of Subject Experience of Nasal Polyps
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI